Sugi Predict

Sugi Predict / Compounds / SCHEMBL299010

SCHEMBL299010

SCHEMBL299010

COc1ccc2nc(Br)sc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.67
▸ CYP2C19 P33261 3/20 0.67
▸ CYP3A4 P08684 2/20 0.67
▸ PDK1 Q15118 1/20 0.65
▸ RAB9A P51151 5/20 0.58
▸ MAPT P10636 4/20 0.58
▸ NPC1 O15118 4/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ TSHR P16473 1/20 0.58
▸ APP P05067 5/20 0.56
▸ HTT P42858 2/20 0.55
▸ DYRK1A Q13627 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ NFKB2 Q00653 1/20 0.55
▸ RELA Q04206 1/20 0.55
▸ GAA P10253 2/20 0.54
▸ GLA P06280 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984320 0.88 APP (0.72) RAB9ANPC1SMN1; SMN2APPGAA
SCHEMBL2400142 0.85 NPC1 (0.55) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL422166 0.81 CYP1A2 (0.67) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL19783432 0.81 KMT2A (0.69) CYP1A2CYP2C19CYP3A4RAB9AMAPT
SCHEMBL483767 0.80 CYP1A2 (0.65) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL7005131 0.80 CYP1A2 (0.65) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL22358 0.80 CYP3A4 (1.00) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL144993 0.80 KMT2A (0.69) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL29683488 0.80 CYP3A4 (1.00) CYP1A2CYP2C19CYP3A4PDK1RAB9A
SCHEMBL5923359 0.80 CYP1A2 (0.65) CYP1A2CYP2C19CYP3A4PDK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684227-A The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor 国电投核素同创(重庆)科技有限公司 2025-03-25 — — CN claimed
CN-112939829-B Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2023-02-21 — — CN claimed
CN-112939829-A Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2021-06-11 — — CN claimed
US-12636385-B2 Selective ligands for tau aggregates SENTONIX, INC. (US) 2026-05-26 — — US disclosed
US-12594264-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-04-07 — — US disclosed
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME CHECKMATE THERAPEUTICS INC. (KR) 2026-01-22 — — US disclosed
CN-119684227-A The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor 国电投核素同创(重庆)科技有限公司 2025-03-25 — — CN disclosed
CN-119684227-A The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor 国电投核素同创(重庆)科技有限公司 2025-03-25 — — CN disclosed
CN-116041341-B Quinazoline PAR4 antagonist and medical application thereof 中国药科大学 2025-02-28 — — CN disclosed
US-12195457-B2 Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD; (CN) 2025-01-14 — — US disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
US-5631268-A ANTIALLERGENS, 5HT2 RECEPTOR ANTAGONISTS MERRELL PHARMACEUTICALS INC. (US) 1997-05-20 — — US disclosed
US-5602147-A Piperidinyl thiacyclic derivatives MERRELL PHARMACEUTICALS INC. (US) 1997-02-11 — — US disclosed
US-5596003-A Piperidinyl thiacyclic derivatives MERRELL PHARMACEUTICALS INC. (US) 1997-01-21 — — US disclosed
US-5541200-A Piperidinyl thiacyclic derivatives MERRELL PHARMACEUTICALS INC. (US) 1996-07-30 — — US disclosed
US-5476861-A Piperidinyl thiacyclic derivatives MERRELL DOW PHARMACEURICALS INC. (US) 1995-12-19 — — US disclosed
EP-0626968-A4 — — 1995-01-04 — — EP disclosed
EP-0626968-A1 PIPERIDINYL THIACYCLIC DERIVATIVES MERRELL PHARMACEUTICALS INC. (US) 1994-12-07 — — EP disclosed
US-5371093-A Piperidinyl thiacyclic derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1994-12-06 — — US disclosed
WO-1993016081-A1 PIPERIDINYL THIACYCLIC DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1993-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 CYP1A2 176/4885CYP2C19 61/4885CYP3A4 18/4885
US-12636385-B2 Selective ligands for tau aggregates MAPT, PSEN2, PSEN1 CYP1A2 4779/4885CYP2C19 4844/4885CYP3A4 4635/4885
US-12594264-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ADRM1, CRBN, SNCA CYP1A2 4662/4885CYP2C19 4877/4885CYP3A4 4665/4885
US-12195457-B2 Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative S1PR1, S1PR2, S1PR3 CYP1A2 1285/4885CYP2C19 1658/4885CYP3A4 1391/4885
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME NAMPT, NAPRT, NNT CYP1A2 1677/4885CYP2C19 2155/4885CYP3A4 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.